These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 1441492)
21. [Evaluation of the effectiveness and tolerability of gliquidone in the treatment of diabetes mellitus type II]. Iori I; Bosi E; Manicardi E; Del Din G; Dini FL; Portioli I Riv Eur Sci Med Farmacol; 1989 Jun; 11(3):277-83. PubMed ID: 2640049 [TBL] [Abstract][Full Text] [Related]
25. Insulin initiation in Type 2 diabetes. Page S Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011 [No Abstract] [Full Text] [Related]
26. Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes. Tildesley HD; Aydin CM; Ignaszewski A; Strelzow JA; Yu E; Bondy G Int J Cardiol; 2007 Feb; 115(3):312-7. PubMed ID: 16824633 [TBL] [Abstract][Full Text] [Related]
27. Failure of sulfonylureas in type 2 diabetes. Yildiz BO; Gürlek A Horm Metab Res; 1999 Apr; 31(4):293-4. PubMed ID: 10333089 [No Abstract] [Full Text] [Related]
28. [Failure of oral hypoglycemic agents: clinical experiences in 20 years' follow-up]. Aylwin CG; López G; García de los Riós M; Vial T; Pinto JL; Ojeda A; Orellana JL Rev Med Chil; 1988 Aug; 116(8):729-35. PubMed ID: 3255124 [No Abstract] [Full Text] [Related]
29. [Experience with diamicron treatment of diabetics]. Velikov VK; Shubina IO; Saltykov BB; Frolova AI Klin Med (Mosk); 1984 Nov; 62(11):99-101. PubMed ID: 6441072 [No Abstract] [Full Text] [Related]
30. Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone. Shimizu H; Monden T; Nagai T; Shoda Y; Sato T; Yamada M; Mori M Diabet Med; 2005 Feb; 22(2):225-6. PubMed ID: 15660744 [No Abstract] [Full Text] [Related]
31. [Oral antidiabetic agents: what are the choices?]. Crausaz FM Rev Med Suisse Romande; 1991 Aug; 111(8):701-5. PubMed ID: 1925244 [No Abstract] [Full Text] [Related]
32. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM). Capriotti T Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992 [No Abstract] [Full Text] [Related]
33. Rational choice of oral antihyperglycaemic agents. Chowdhury S; Sengupta N J Indian Med Assoc; 2002 Mar; 100(3):174-5, 177. PubMed ID: 12408278 [TBL] [Abstract][Full Text] [Related]
34. Treatment choices for managing hyperglycaemia in patients with type 2 diabetes and moderate to severe renal disease. Palmer F; Prior SL; Mallipedhi A; Jones DA; Price DE; Stephens JW Diabetes Res Clin Pract; 2012 Aug; 97(2):e23-4. PubMed ID: 22776145 [No Abstract] [Full Text] [Related]
36. Could FFAR1 assist insulin secretion in type 2 diabetes? Bailey CJ Lancet; 2012 Apr; 379(9824):1370-1. PubMed ID: 22374407 [No Abstract] [Full Text] [Related]
37. The benefit of increasing sulfonylurea dose. Epstein MD Ann Intern Med; 1993 Sep; 119(6):537-8. PubMed ID: 8357128 [No Abstract] [Full Text] [Related]
38. The benefit of increasing sulfonylurea dose. Feinglos MN; Hollis CR Ann Intern Med; 1993 Sep; 119(6):537; author reply 538. PubMed ID: 8357127 [No Abstract] [Full Text] [Related]
39. [Mortality among the sulphonylureas]. Seguí Díaz M Semergen; 2015 Oct; 41(7):393-4. PubMed ID: 25840739 [No Abstract] [Full Text] [Related]
40. [The outlines of JEDIS-2, the new version of Japan Early Diabetes Intervension Study (JEDIS)]. Kawazu S; Iwamoto Y; Kanazawa Y; Kuzuya T Nihon Rinsho; 2010 Nov; 68 Suppl 9():77-86. PubMed ID: 21667470 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]